Figure 7 | British Journal of Cancer

Figure 7

From: Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis

Figure 7

In vivo testing of glycoengineered PR1A3. Survival was measured in SCID/beige mice treated with either glycomodified humanised IgG1 PR1A3 (▵), glycomodified IgG1 SM3E (□) or vehicle control (⋄) (n=10 in each treatment group). Y-axis represents % survival and x-axis represents number of days after injection of tumour. Both SM3E and PR1A3 increased survival significantly when compared with the vehicle control (P<0.05). There was no significant difference in survival between SM3E and PR1A3 treatments.

Back to article page